Switch to:
Also traded in: Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GILD's Cash to Debt is ranked higher than
99% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GILD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GILD' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.54 Max: 4122.75
Current: No Debt
0.15
4122.75
Equity to Asset 0.37
GILD's Equity to Asset is ranked lower than
79% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GILD: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
GILD' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.60 Max: 0.95
Current: 0.37
0.21
0.95
Interest Coverage 32.26
GILD's Interest Coverage is ranked lower than
84% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 32.26 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 37.05 Max: 2509.2
Current: 32.26
11.11
2509.2
F-Score: 8
Z-Score: 5.14
M-Score: -1.92
WACC vs ROIC
11.70%
127.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 68.00
GILD's Operating margin (%) is ranked higher than
97% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. GILD: 68.00 )
Ranked among companies with meaningful Operating margin (%) only.
GILD' s Operating margin (%) Range Over the Past 10 Years
Min: -25.07  Med: 50.02 Max: 61.33
Current: 68
-25.07
61.33
Net-margin (%) 55.48
GILD's Net-margin (%) is ranked higher than
97% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. GILD: 55.48 )
Ranked among companies with meaningful Net-margin (%) only.
GILD' s Net-margin (%) Range Over the Past 10 Years
Min: -39.32  Med: 36.80 Max: 48.62
Current: 55.48
-39.32
48.62
ROE (%) 105.99
GILD's ROE (%) is ranked higher than
100% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. GILD: 105.99 )
Ranked among companies with meaningful ROE (%) only.
GILD' s ROE (%) Range Over the Past 10 Years
Min: -49.14  Med: 45.97 Max: 90.32
Current: 105.99
-49.14
90.32
ROA (%) 42.18
GILD's ROA (%) is ranked higher than
99% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. GILD: 42.18 )
Ranked among companies with meaningful ROA (%) only.
GILD' s ROA (%) Range Over the Past 10 Years
Min: -30.31  Med: 27.37 Max: 42.28
Current: 42.18
-30.31
42.28
ROC (Joel Greenblatt) (%) 701.72
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. GILD: 701.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GILD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -71.55  Med: 176.02 Max: 484.47
Current: 701.72
-71.55
484.47
Revenue Growth (3Y)(%) 41.70
GILD's Revenue Growth (3Y)(%) is ranked higher than
89% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GILD: 41.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GILD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 35.05 Max: 71.8
Current: 41.7
5.3
71.8
EBITDA Growth (3Y)(%) 55.60
GILD's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. GILD: 55.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GILD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.1  Med: 33.80 Max: 119
Current: 55.6
-9.1
119
EPS Growth (3Y)(%) 60.60
GILD's EPS Growth (3Y)(%) is ranked higher than
95% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. GILD: 60.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GILD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.7  Med: 26.90 Max: 143.3
Current: 60.6
-19.7
143.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GILD Guru Trades in Q1 2015

Lee Ainslie 2,650 sh (New)
David Dreman 5,580 sh (New)
Murray Stahl 8,700 sh (New)
Louis Moore Bacon 44,389 sh (New)
NWQ Managers 113,100 sh (New)
John Buckingham 45,281 sh (New)
Jim Simons 4,032,048 sh (+328.30%)
John Burbank 45,652 sh (+20.93%)
Mario Gabelli 49,470 sh (+16.13%)
John Rogers 891,645 sh (+11.07%)
Joel Greenblatt 1,107,732 sh (+9.73%)
Steven Cohen 1,158,000 sh (+9.13%)
Ken Fisher 789,615 sh (+2.35%)
Jeremy Grantham 4,600 sh (unchged)
NWQ Managers 55,200 sh (unchged)
Leon Cooperman Sold Out
Alan Fournier Sold Out
Ronald Muhlenkamp 218,740 sh (-0.09%)
Pioneer Investments 3,046,688 sh (-4.22%)
Dodge & Cox 4,250 sh (-5.76%)
RS Investment Management 144,820 sh (-23.96%)
Julian Robertson 231,511 sh (-56.64%)
Paul Tudor Jones 6,535 sh (-94.02%)
Ray Dalio 25,221 sh (-95.31%)
First Eagle Investment 400 sh (-99.97%)
» More
Q2 2015

GILD Guru Trades in Q2 2015

Westport Asset Management 95,000 sh (New)
John Hussman 75,000 sh (New)
Ray Dalio 81,721 sh (+224.02%)
Julian Robertson 399,411 sh (+72.52%)
David Dreman 9,525 sh (+70.70%)
Paul Tudor Jones 10,380 sh (+58.84%)
NWQ Managers 145,200 sh (+28.38%)
John Buckingham 57,343 sh (+26.64%)
John Rogers 1,106,494 sh (+24.10%)
Pioneer Investments 3,274,401 sh (+7.47%)
Murray Stahl 8,950 sh (+2.87%)
Ken Fisher 791,630 sh (+0.26%)
Dodge & Cox 4,250 sh (unchged)
First Eagle Investment 400 sh (unchged)
Steven Cohen Sold Out
Ronald Muhlenkamp 218,620 sh (-0.05%)
Joel Greenblatt 1,068,128 sh (-3.58%)
Mario Gabelli 43,925 sh (-11.21%)
Lee Ainslie 2,340 sh (-11.70%)
RS Investment Management 125,840 sh (-13.11%)
Jeremy Grantham 3,600 sh (-21.74%)
Louis Moore Bacon 19,142 sh (-56.88%)
Jim Simons 1,310,100 sh (-67.51%)
John Burbank 2,295 sh (-94.97%)
» More
Q3 2015

GILD Guru Trades in Q3 2015

John Keeley 29,029 sh (New)
John Burbank 29,586 sh (+1189.15%)
Ray Dalio 222,121 sh (+171.80%)
RS Investment Management 156,503 sh (+24.37%)
John Rogers 1,313,500 sh (+18.71%)
David Dreman 11,228 sh (+17.88%)
NWQ Managers 169,500 sh (+16.74%)
Murray Stahl 9,950 sh (+11.17%)
John Buckingham 61,912 sh (+7.97%)
Pioneer Investments 3,283,529 sh (+0.28%)
First Eagle Investment 400 sh (unchged)
John Hussman 75,000 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Lee Ainslie 2,340 sh (unchged)
Dodge & Cox 4,250 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
Louis Moore Bacon Sold Out
Ronald Muhlenkamp 217,990 sh (-0.29%)
Mario Gabelli 43,750 sh (-0.40%)
Julian Robertson 352,311 sh (-11.79%)
Joel Greenblatt 936,982 sh (-12.28%)
Ken Fisher 562,391 sh (-28.96%)
Paul Tudor Jones 7,300 sh (-29.67%)
Jim Simons 280,300 sh (-78.60%)
» More
Q4 2015

GILD Guru Trades in Q4 2015

Diamond Hill Capital 2,070 sh (New)
T Rowe Price Equity Income Fund 1,250,000 sh (New)
Jeff Auxier 2,282 sh (New)
John Buckingham 63,796 sh (+3.04%)
Ken Fisher 563,917 sh (+0.27%)
John Hussman Sold Out
Ronald Muhlenkamp 217,975 sh (-0.01%)
Mario Gabelli 42,700 sh (-2.40%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 8.00
GILD's P/E(ttm) is ranked higher than
90% of the 374 Companies
in the Global Biotechnology industry.

( Industry Median: 35.73 vs. GILD: 8.00 )
Ranked among companies with meaningful P/E(ttm) only.
GILD' s P/E(ttm) Range Over the Past 10 Years
Min: 7.61  Med: 20.48 Max: 45.49
Current: 8
7.61
45.49
Forward P/E 5.79
GILD's Forward P/E is ranked higher than
87% of the 347 Companies
in the Global Biotechnology industry.

( Industry Median: 16.47 vs. GILD: 5.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 8.10
GILD's PE(NRI) is ranked higher than
90% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 33.50 vs. GILD: 8.10 )
Ranked among companies with meaningful PE(NRI) only.
GILD' s PE(NRI) Range Over the Past 10 Years
Min: 7.61  Med: 20.48 Max: 45.49
Current: 8.1
7.61
45.49
P/B 6.98
GILD's P/B is ranked lower than
89% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. GILD: 6.98 )
Ranked among companies with meaningful P/B only.
GILD' s P/B Range Over the Past 10 Years
Min: 4.16  Med: 8.42 Max: 18.79
Current: 6.98
4.16
18.79
P/S 4.36
GILD's P/S is ranked higher than
73% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. GILD: 4.36 )
Ranked among companies with meaningful P/S only.
GILD' s P/S Range Over the Past 10 Years
Min: 3.53  Med: 8.11 Max: 14.41
Current: 4.36
3.53
14.41
PFCF 7.72
GILD's PFCF is ranked higher than
91% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 27.59 vs. GILD: 7.72 )
Ranked among companies with meaningful PFCF only.
GILD' s PFCF Range Over the Past 10 Years
Min: 7.3  Med: 22.01 Max: 59.09
Current: 7.72
7.3
59.09
POCF 7.40
GILD's POCF is ranked higher than
91% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 25.75 vs. GILD: 7.40 )
Ranked among companies with meaningful POCF only.
GILD' s POCF Range Over the Past 10 Years
Min: 7  Med: 20.02 Max: 52.27
Current: 7.4
7
52.27
EV-to-EBIT 6.20
GILD's EV-to-EBIT is ranked higher than
76% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.26 vs. GILD: 6.20 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 14.40 Max: 209.2
Current: 6.2
-154.2
209.2
EV-to-EBITDA 5.90
GILD's EV-to-EBITDA is ranked higher than
76% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 17.11 vs. GILD: 5.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 13.55 Max: 168
Current: 5.9
-189.9
168
PEG 0.30
GILD's PEG is ranked higher than
94% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. GILD: 0.30 )
Ranked among companies with meaningful PEG only.
GILD' s PEG Range Over the Past 10 Years
Min: 0.18  Med: 1.00 Max: 3.83
Current: 0.3
0.18
3.83
Shiller P/E 33.14
GILD's Shiller P/E is ranked higher than
75% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 45.84 vs. GILD: 33.14 )
Ranked among companies with meaningful Shiller P/E only.
GILD' s Shiller P/E Range Over the Past 10 Years
Min: 26.54  Med: 61.04 Max: 2078
Current: 33.14
26.54
2078
Current Ratio 2.77
GILD's Current Ratio is ranked lower than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GILD: 2.77 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 6.81 Max: 20.42
Current: 2.77
1.09
20.42
Quick Ratio 2.56
GILD's Quick Ratio is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GILD: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 6.28 Max: 20.42
Current: 2.56
0.83
20.42
Days Inventory 169.03
GILD's Days Inventory is ranked lower than
63% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. GILD: 169.03 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 148.53  Med: 228.99 Max: 328.95
Current: 169.03
148.53
328.95
Days Sales Outstanding 65.46
GILD's Days Sales Outstanding is ranked lower than
51% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GILD: 65.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.89  Med: 71.19 Max: 84.93
Current: 65.46
65.89
84.93
Days Payable 112.89
GILD's Days Payable is ranked higher than
71% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. GILD: 112.89 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 92.02  Med: 172.89 Max: 309.16
Current: 112.89
92.02
309.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.45
GILD's Dividend Yield is ranked higher than
62% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. GILD: 1.45 )
Ranked among companies with meaningful Dividend Yield only.
GILD' s Dividend Yield Range Over the Past 10 Years
Min: 0.36  Med: 0.80 Max: 1.04
Current: 1.45
0.36
1.04
Dividend Payout 0.08
GILD's Dividend Payout is ranked higher than
91% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. GILD: 0.08 )
Ranked among companies with meaningful Dividend Payout only.
GILD' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.14 Max: 0.15
Current: 0.08
0.14
0.15
Forward Dividend Yield 1.97
GILD's Forward Dividend Yield is ranked higher than
68% of the 217 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. GILD: 1.97 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.45
GILD's Yield on cost (5-Year) is ranked lower than
51% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. GILD: 1.45 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GILD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.36  Med: 0.80 Max: 1.53
Current: 1.45
0.36
1.53
3-Year Average Share Buyback Ratio -1.40
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. GILD: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.5  Med: -2.40 Max: 6.2
Current: -1.4
-15.5
6.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.35
GILD's Price/Tangible Book is ranked lower than
87% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 3.93 vs. GILD: 17.35 )
Ranked among companies with meaningful Price/Tangible Book only.
GILD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.08  Med: 9.57 Max: 214.73
Current: 17.35
2.08
214.73
Price/Projected FCF 1.16
GILD's Price/Projected FCF is ranked higher than
88% of the 296 Companies
in the Global Biotechnology industry.

( Industry Median: 3.14 vs. GILD: 1.16 )
Ranked among companies with meaningful Price/Projected FCF only.
GILD' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.77  Med: 2.17 Max: 20.83
Current: 1.16
0.77
20.83
Price/Median PS Value 0.54
GILD's Price/Median PS Value is ranked higher than
75% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. GILD: 0.54 )
Ranked among companies with meaningful Price/Median PS Value only.
GILD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.47  Med: 1.42 Max: 5.5
Current: 0.54
0.47
5.5
Price/Peter Lynch Fair Value 0.32
GILD's Price/Peter Lynch Fair Value is ranked higher than
97% of the 111 Companies
in the Global Biotechnology industry.

( Industry Median: 1.67 vs. GILD: 0.32 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GILD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.36  Med: 1.04 Max: 9.13
Current: 0.32
0.36
9.13
Price/Graham Number 2.81
GILD's Price/Graham Number is ranked higher than
52% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 2.43 vs. GILD: 2.81 )
Ranked among companies with meaningful Price/Graham Number only.
GILD' s Price/Graham Number Range Over the Past 10 Years
Min: 1.64  Med: 3.62 Max: 15.78
Current: 2.81
1.64
15.78
Earnings Yield (Greenblatt) (%) 16.10
GILD's Earnings Yield (Greenblatt) (%) is ranked higher than
93% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. GILD: 16.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GILD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 6.50 Max: 16
Current: 16.1
0.5
16
Forward Rate of Return (Yacktman) (%) 47.62
GILD's Forward Rate of Return (Yacktman) (%) is ranked higher than
95% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. GILD: 47.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GILD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.7  Med: 5.60 Max: 47.6
Current: 47.62
0.7
47.6

More Statistics

Revenue(Mil) $32639
EPS $ 11.92
Beta1.41
Short Percentage of Float1.45%
52-Week Range $81.89 - 123.37
Shares Outstanding(Mil)1441.18

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 33,301 36,819 42,403
EPS($) 12.98 15.08 18.72
EPS without NRI($) 12.98 15.08 18.72

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for NAS:GILD

Headlines

Articles On GuruFocus.com
Jeff Auxier Takes Plunge in Fastenal, a Stock From Watchlist Feb 10 2016 
Plenty of Opportunity to Buy Individual Stocks: John Buckingham Feb 02 2016 
Apple: Think Differently From the Analysts Feb 01 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
The Best Reason to Love Gilead's Market Correction Jan 18 2016 
Gurus Are Buying These Stocks Trading Below Peter Lynch value Jan 14 2016 
Best Ideas Contest 2016, Win $1000 Jan 28 2016 
Berkshire Hathaway: Dividends Are Coming; Why Not In 2016? Dec 31 2015 
Here are My Top Ten Stock Picks for 2016 Dec 30 2015 
Ackman, Sequoia Stock Valeant Changes Course Dec 21 2015 

More From Other Websites
Gilead (GILD) Stock Gains, Barclays Sees Upside Potential for Hep-C Drugs Feb 10 2016
Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
Gilead Sciences: A Good Set Up for Earnings Beats? Feb 10 2016
Major Biotech Short Interest Continues to Be Mixed Feb 10 2016
Icahn, Gilead, GE Lead Top Insider Trades Of The Week Feb 09 2016
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
What Investors Can Expect from Healthcare Sector Companies Feb 09 2016
Rebound For Big Biotech ETF Will Require Some Patience Feb 09 2016
[$$] Overheard: Biotech Waiting Game Still Paying Off for Gilead Feb 09 2016
[$$] OVERHEARD Feb 08 2016
Gilead Sciences to Participate in Two Upcoming Investor Conferences Feb 08 2016
Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA Feb 08 2016
Biotech Waiting Game Still Paying Off For Gilead Feb 08 2016
Why GoPro, Microsoft, Twitter and Two Other Stocks Are in Spotlight Today Feb 08 2016
Why Gilead Sciences (GILD) Stock May Advance Today Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK